Posts tagged “BDSI”
Raleigh-based BioDelivery Sciences will receive a $10 million milestone payment from partner Endo Pharmaceuticals now that the FDA has accepted a new drug application for the severe pain reliever system known as Belbuca.
Apple's blowout quarter; ChannelAdvisor adds Jet; AT&T revenue up 4%; BDSI to relaunch pain drug; Snapchat's media deal
In today's Bulldog wrapup of technology and life science news: Apple reports a blowout quarter; ChannelAdvisor adds new service; AT&T grows revenue but books $4B loss; BDSI to relaunch pain treatment; Sanpchat to show media news.
More than two million people suffer from opioid dependence in the United States. BioDelivery's FDA approval for Bunavail may open up tremendous revenue streams for the Raleigh-based drug company.
Raleigh-based BioDelivery Sciences recently raised $60 million to help commercialize its proposed chronic pain reliever drug and hopes to win FDA approval for it in June. On Thursday, BDSI said it had chosen Durham-based Quintiles, the world's largest life science services firm, to help take the drug to market. The deal includes formation of a sales force.
Capitalizing on news that its chronic pain drug BEMA buprenorphine showed positive top-line phase III clinical trial results, BioDelivery Sciences International is raising $60 million to finance commercialization efforts.
Chronic pain drug BEMA buprenorphine showed positive top-line phase III clinical trial results, and securing trial data for further analysis has triggered a $10 million milestone to BioDelivery Sciences International.
BioDelivery Sciences International's opioid dependence treatment Bunavail faces an FDA decision date of June 7 and the Raleigh company is getting ready to go to market if it secures regulatory approval.
BioDelivery Sciences invested a mix of stock and cash that could total nearly $40 million if a proposed gel to treat diabetic neuropathy pain wins FDA approval, and the company says it will proceed with further tests after a "positive" meeting with regulators.
The Raleigh-based drug delivery technology firm projects sales of up to $250 million if the opioid dependence treatment wins FDA approval next year.
BioDelivery Sciences International's current pipeline reflects a shift in direction and a effort to stretch beyond the drug-delivery technology that was the initial focus for the company. Learn more about BDSI's strategy.
BioDelivery Sciences strikes a deal to license a potential treatment for diabetic neuropathy with privately held Arcion Therapeutics. The mix of stock and cash could total nearly $40 million if the drug wins approval.
Institutional investors have agreed to buy nearly 6.8 million of BDSI common shares and 2.7 million of newley designated Series A convertible preferred stock for an aggregate price of $4.21 each.
- Reddit, Google crack down on nude photos; GSK-Novartis deal nears close; Apple loses $539.M dispute; INC's first results; honor for Quintiles
- GSK's nonprescription diet pill 'alli' back in stores after recall
- Bronto's upbeat update; IBM targets hybrid cloud; Quintiles' new exec; YouTube for Kids half-baked?; Comcast earnings